UCB Competitors
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts | Market Cap |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and | Outperform |
16
|
$807.43 | $636.99 | 8.68% | 9 | $727.01B |
| JNJ | Johnson & Johnson | Outperform |
9
|
$146.97 | $174.55 | 15.67% | 3 | $353.71B |
| MRK | Merck | Outperform |
2
|
$129.49 | $130.51 | 11.21% | 11 | $327.97B |
| ABBV | AbbVie | Outperform |
9
|
$157.06 | $178.42 | 16.20% | 11 | $277.35B |
| TMO | Thermo Fisher Scientific | Outperform |
10
|
$584.05 | $591.94 | 6.16% | 1 | $222.94B |
| NOVN | Novartis | Hold |
10
|
CHF91.74 | CHF105.00 | 17.31% | 9 | CHF187.19B |
| AMGN | Amgen | Outperform |
4
|
$305.84 | $303.65 | 5.38% | 8 | $164.06B |
| SAN | Sanofi | Outperform |
16
|
89.52€ | 102.80€ | 21.76% | 9 | 111.91€B |
| CSL | CSL | Outperform |
12
|
$280.92 | $205.51 | -26.86% | 5 | $135.76B |
| BMY | Bristol-Myers Squibb | Hold |
2
|
$41.24 | $58.15 | 30.94% | 10 | $83.60B |
| GILD | Gilead Sciences Inc | Outperform |
11
|
$65.68 | $87.82 | 21.80% | 14 | $81.83B |
| SHW | Sherwin Williams | Outperform |
15
|
$304.84 | $317.38 | 13.65% | 9 | $77.32B |
| 4502 | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.13k | ¥4.74k | 11.27% | 0 | ¥6.49T |
| LONN | Lonza Group | Buy |
16
|
CHF515.20 | CHF516.89 | 16.46% | 8 | CHF37.15B |
| PPG | PPG Industries | Outperform |
13
|
$131.42 | $159.04 | 18.70% | 1 | $30.93B |
| TEVA | Teva Pharmaceutical Industries | Outperform |
12
|
$16.60 | $11.59 | 2.41% | 9 | $18.80B |
| 4523 | Eisai | Outperform |
18
|
¥6.76k | ¥9.58k | 24.19% | 0 | ¥1.97T |
| INCY | Incyte | Outperform |
9
|
$57.31 | $77.05 | 36.64% | 8 | $12.01B |
| CRDA | Croda International Plc | Outperform |
18
|
£46.29 | £65.12 | 10.17% | 6 | £6.81B |
| WCH | Wacker Chemie | Outperform |
17
|
101.45€ | 145.36€ | 23.21% | 9 | 5.00€B |
| APLS | Apellis Pharmaceuticals | Outperform |
6
|
$40.61 | $79.81 | 104.38% | 3 | $5.16B |
| CLN | Clariant | Outperform |
18
|
CHF15.01 | CHF16.11 | 6.60% | 6 | CHF4.67B |
| OMER | Omeros | Hold |
11
|
$3.35 | $13.00 | -100.00% | 2 | $241.63M |
| XFOR | X4 Pharmaceuticals | Outperform |
4
|
$0.90 | $3.26 | 455.56% | 1 | $183.05M |
| DXB | Dimerix |
0
|
$0.34 | $0.00 | 70.59% | 0 | $186.89M | |
| IFRX | InflaRx N.V. | Outperform |
4
|
$1.44 | $9.44 | 416.67% | 2 | $85.38M |
| BLRX | BioLineRx | - |
7
|
₪0.17 | ₪1.39 | -100.00% | 0 | ₪190.66M |
| AKTX | Akari Therapeutics, Plc | - |
2
|
$1.95 | $80.00 | -100.00% | 0 | $9.39M |